论文部分内容阅读
目的:探讨排卵障碍患者用来曲唑方案与尿促性腺激素方案对子宫内膜形态的影响。方法:回顾性分析2009年1月-2011年4月我院门诊就诊的排卵障碍患者60例,共计80个促排卵周期,其中,来曲唑组34个周期,尿促性激素组46个促排卵周期。比较hCG日两组间子宫内膜厚度,形态,优势卵泡数目、排卵数及妊娠结局。结果hCG日来曲唑组子宫内膜厚度为8.700±2.6952mm,尿促性腺素组子宫内膜厚度为9.463±1.9537mm,P>0.05,差异无统计学意义,但在形态上,来曲唑组子宫内膜A、A-B型为52.9%,而尿促性腺激素组为16.5%两组间差异有统计学意义。来曲唑组平均优势卵泡个数为1.4706±1.3311,尿促性激素组为3.5217±4.0756个,两者比较,P<0.05,差异有统计学意义。结论:排卵障碍患者用来曲唑方案与尿促性腺激素方案相比并不降低周期妊娠率,且来曲唑方案有更明显的单卵泡发生率,可获得更好的子宫内膜形态。
Objective: To investigate the effect of letrozole and urinary gonadotropin regimen on the morphology of endometrium in patients with ovulation disorders. Methods: A retrospective analysis of 60 patients with ovulation disorders in our hospital from January 2009 to April 2011, a total of 80 ovulation cycles, of which, 34 cycles of letrozole group, 46 ovulation promoting hormone group 46 ovulation cycle. Endometrial thickness, morphology, number of dominant follicles, number of ovulation and pregnancy outcome were compared between the two groups on day hCG. Results The thickness of endometrium in letrozole group was 8.700 ± 2.6952 mm on hCG day, and the thickness of endometrium in urine gonadotropin group was 9.463 ± 1.9537 mm (P> 0.05), but the difference was not statistically significant Group A, AB type of 52.9%, while the group of urinary gonadotropin 16.5% difference between the two groups was statistically significant. The average number of dominant follicles in letrozole group was 1.4706 ± 1.3311, and that of urinary hormone group was 3.5217 ± 4.0756. There was significant difference between the two groups (P <0.05). CONCLUSIONS: The use of letrozole in patients with ovulation disorders does not reduce the rate of cycle pregnancy compared with urinary gonadotropin regimen, and levsoxazone has a more pronounced incidence of single follicles and leads to better endometrial morphology.